When was Xellar founded?

Xellar was founded in 2022 and raised its 1st funding round within a year of its incorporation.

Where is Xellar located?

Xellar is headquartered in Cambridge, United States.

How many employees does Xellar have?

As of Mar 31, 2026, the latest employee count at Xellar is 27.

Is Xellar a funded company?

Xellar is a funded company, having raised a total of $24M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Aug 30, 2022.

When was the latest funding round of Xellar?

Xellar's latest funding was a $***** Series A round on Jul 17, 2024, with participation from 4 investors.

Where does Xellar rank among its competitors?

Xellar ranks 23rd amongst 155 active competitors, of which 65 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Tandem AI, which secured $22M in Nov, 2025.

Who are the top competitors of Xellar?

Xellar's top competitors include Recursion Pharmaceuticals, Healx and XtalPi. Among them, Tandem AI secured the most recent funding round in November, 2025.

Xellar - 2026 Company Profile, Team, Funding & Competitors

Xellar is a series A company based in Cambridge (United States), founded in 2022 by Xin Xie. It operates as a Developer of an AI-based computational platform for drug discovery. Xellar has raised $24M in funding from Zhen Fund and Legend Capital. The company has 155 active competitors, including 65 funded and 11 that have exited. Its top competitors include companies like Recursion Pharmaceuticals, Healx and XtalPi.

Company Details

Developer of an AI-based computational platform for drug discovery. It offers microfluidic-based Organ-on-a-Chip technology with high throughput screening, content imaging, and machine learning-based data analysis for drug discovery and development.

Website: xellarbio.com
Email ID: *****@xellarbio.com

Key Metrics

Founded Year

2022

Location

Cambridge, United States

Stage

Series A

Total Funding

$24M in 2 rounds

Latest Funding Round

Series A, Jul 17, 2024, $*****

Investors

Zhen Fund & 6 more

Ranked

23^rd among 155 active competitors

Employee Count

27 as on Mar 31, 2026

Similar Companies

Recursion Pharmaceuticals & 184 more

View Xellar's full profile

Xellar has raised a total funding of $24M over 2 rounds. Its first funding round was on Aug 30, 2022. Its latest funding round was a Series A round on Jul 17, 2024 for $*****. 4 investors participated in its latest round. Xellar has 7 institutional investors.

Here is the list of recent funding rounds of Xellar:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 17, 2024	8619083	Series A	8653431	2863884	5295167	8684242
Aug 30, 2022	1724467	Seed	8476638	9049913	Zhen Fund & 1 more	Yayi Capital

Access funding benchmarks and valuations. Sign up today!

View details of Xellar's funding rounds and investors

The founders of Xellar is Xin Xie.

Here are the details of Xellar's key team members:

Xin Xie: Co-Founder of Xellar.
Contact Info: 1 email address

View details of Xellar's Founder profiles and Board Members

Xellar's employee count trend

Xellar has 27 employees as of Mar 26. Here is Xellar's employee count trend over the years:

Uncover Xellar's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Xellar include Recursion Pharmaceuticals, Healx and XtalPi. Here is the list of Top 10 competitors of Xellar, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Recursion Pharmaceuticals 2013, New York (United States), Public	AI-enabled drug discovery and development platform for novel therapeutics	$452M	Baillie Gifford, Felicis Ventures & 46 others	72/100
2nd	Healx 2014, Cambridge (United Kingdom), Series C	AI-powered drug discovery platform to treat rare diseases	$115M	Atomico, Balderton Capital & 18 others	69/100
3rd	XtalPi 2014, Cambridge (United States), Public	AI-based drug research and development company	$785M	SoftBank Vision Fund, Tencent & 25 others	67/100
4th	Schrodinger 1990, New York City (United States), Acquired	Provider of a web-based simulation and modelling tool	$162M	Gates Foundation, WuXi AppTec & 16 others	66/100
5th	Xaira 2023, San Francisco (United States), Series D	AI-enabled platform for drug discovery and development	$1B	Arch Venture Partners, Foresite Labs & 11 others	63/100
6th	METiS Therapeutics 2017, Cambridge (United States), Series B	Provider of an AI-assisted platform for drug discovery and development	$252M	Sequoia Capital China, Luminous Ventures ... & 13 others	63/100
7th	Valo Health 2019, Boston (United States), Series B	AI-powered platform for drug discovery and development	$450M	PSP Investments, Koch Disruptive Technologies ... & 7 others	62/100
8th	In Silico 2014, Cambridge (United States), Public	AI-enabled bioinformatics platform for drug discovery and biomarker development	$510M	Qiming Venture Partners, Warburg Pincus & 36 others	62/100
9th	Gero 2015, Singapore (Singapore), Series A	Developer of reverse engineering technology for controlling aging	$13.5M	Bulba Ventures, Melnichek Investments & 13 others	62/100
10th	Tandem AI 2021, New York (United States), Series A	AI-based drug discovery tool for researchers	$82M	Orbimed, Qiming Venture Partners & 4 others	62/100
23rd	Xellar 2022, Cambridge (United States), Series A	Developer of an AI-based computational platform for drug discovery	$24M	Yael Capital, Zhengxuan Investment & 5 others	53/100